recast-jats-buildd8e1462159jitcJ Immunother CancerjitcJournal for ImmunoTherapy of CancerJ Immunother CancerJ Immunother Cancer2051-1426BMJ Publishing Group Ltdjitc-2020-002277corr110.1136/jitc-2020-002277corr1/jitc/9/6/e002277corr1.atomCorrectionOpen accessSpecial collectionsOpen accessCorrection: Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score62021156202116202116202196e002277corr1© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.2021https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.special-featureunlocked

Dettorre GM, Dolly S, Loizidou A, On behalf of OnCovid study group et al. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. J Immunother Cancer 2021;9:e002277. doi: 10.1136/jitc-2020-002277

This paper has been updated to amend author affiliations.